
AKTS Stock Forecast & Price Target
AKTS Analyst Ratings
Bulls say
Aktis Oncology is positioned to potentially succeed in a growing market as they focus on expanding the potential of targeted radiopharmaceuticals for solid tumor cancers. With a strong collaboration agreement and promising pipeline, the company has the resources and expertise to drive value for shareholders and patients alike.
Bears say
Aktis Oncology is facing potential financial challenges with their current portfolio and pipeline. Although they have promising results with their Nectin-4 targeting drug, [225Ac]Ac-AKY-1189, as well as partnerships and designations for their other drugs, the company may struggle to fund their research and development efforts. This could hinder their ability to bring products to market and generate revenue, ultimately affecting their stock price.
This aggregate rating is based on analysts' research of Aktis Oncology Inc and is not a guaranteed prediction by Public.com or investment advice.
AKTS Analyst Forecast & Price Prediction
Start investing in AKTS
Order type
Buy in
Order amount
Est. shares
0 shares